Related Experiment Video

Updated: Jun 29, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

Losartan decreased premature ventricular contractions in patients with hypertension

H Shiraishi, T Shirayama, T Sakamoto

    Journal of Human Hypertension
    |October 10, 2008
    PubMed

    Insights

    Losartan, enalapril, and amlodipine effectively lowered blood pressure and reduced premature ventricular contractions (PVCs) in patients with essential hypertension. Losartan demonstrated the most significant impact on both metrics.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Hypertension Research

    Background:

    • Essential hypertension is a common condition associated with cardiovascular risks.
    • Premature ventricular contractions (PVCs) can occur in hypertensive patients and may indicate underlying cardiac issues.

    Purpose of the Study:

    • To evaluate the efficacy of losartan, enalapril, and amlodipine in managing essential hypertension.
    • To assess the impact of these antihypertensive drugs on reducing PVCs.

    Main Methods:

    • A comparative study involving patients diagnosed with essential hypertension.
    • Administration of losartan, enalapril, or amlodipine to assess changes in blood pressure and PVC frequency.

    Main Results:

    • All three drugs, losartan, enalapril, and amlodipine, significantly reduced blood pressure.
    • A notable decrease in the number of premature ventricular contractions (PVCs) was observed with all treatments.
    • Losartan exhibited a more pronounced effect in reducing both blood pressure and PVCs compared to enalapril and amlodipine.

    Conclusions:

    • Losartan, enalapril, and amlodipine are effective in managing essential hypertension and associated PVCs.
    • Losartan presents a superior therapeutic profile for patients with essential hypertension experiencing PVCs.

    Related Concept Videos

    Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

    Antihypertensive Drugs: Angiotensin II Receptor Blockers

    In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

    Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
    Antihypertensive Drugs: Direct Renin Inhibitors01:25

    Antihypertensive Drugs: Direct Renin Inhibitors

    The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...